UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
|Slideshows|February 10, 2017
Geriatric Psychiatry Research Update
Author(s)Mark L. Fuerst
Highlights of 3 recent studies that focus on psychiatric disorders in older adults.
Advertisement
References:
1. Karlamangla AS, Lachman ME, Han W, et al.
2. Moore TJ, Mattison DR.
3. Novak P, Schmidt R, Kontsekova E, et al.
Advertisement
Related to this article
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
4
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
5